Author(s): Junise V*, R Saraswathi
Only a small fraction of the total dose reaches the lungs after oral administration of Anti-tubercular drug. Pulmonary route can avoid the daily dosing, as it deliver drug directly to the diseased organ and also reduce systemic toxicity of the drugs. Drug-loaded nanoparticles have the potential to be used for pulmonary delivery of therapeutics for treating lung diseases. The objective of our study is to load first line antitubercular drug, Isoniazid in chitosan Nanoparticles in order to enhance bioavailability and to reduce dose frequency. Nanoparticles were formulated by ionotropic gelation method using different concentration of chitosan [2:3, 3:3, 4:3, 5:3 %w/v (chitosan-drug ratio)]. Drug was dispersed in Chitosan in acetic acid solution, into which Sodium Tripolyphosphate solution is added drop wise with continuous stirring and followed by sonication for 5 min. The resulting Chitosan nanoparticle suspension was centrifuged at 16,000 rpm for 30 min and Nanoparticles were collected after freeze drying. Formulation no 2 (F2) shows maximum drug loading and In vitro drug release. The positive zeta value was obtained due to positive charge of polymer used in preparation of dispersion.SEM study revealed that the cross linked chitosan nanoparticles have smooth surface. Pharmacokineticevaluationshowsalltheformulationshowsfirstorder ratereleaseprofile and release mechanism from nanoparticles is diffusion controlled. Stability studies conducted as per ICH guidelines indicated that the developed chitosan nanoparticles are physically and chemically stable and retain their pharmaceutical properties at various environmental conditions over a period of 3 months. From all these results it concludes that formulation No 2 is the best formulation and which is recommended for future studies like Nano dry powder preparation.